目的 分析美托洛爾聯合貝那普利對慢性充血性心力衰竭（CHF）患者心功能及血漿N-末端B型利鈉肽原（NT-proBNP）水平的影響。方法 選取2015年12月-2016年12月就診于青海省人民醫(yī)院的CHF患者210例，根據隨機數表法將其分為3組，各70例。3組均予以常規(guī)檢查及強心、利尿治療，在此基礎上，對照A組單純加用貝那普利治療，對照B組單純加用美托洛爾治療，觀察組聯合美托洛爾與貝那普利治療。比較3組治療前后心功能、運動耐力、NT-proBNP水平、血紅蛋白（Hb）濃度、心率、血壓、臨床療效及安全性。結果 治療前，3組心功能指標、運動耐力、NT-pro BNP水平、Hb含量、心率、血壓相比，差異無統(tǒng)計學意義；治療后，3組以上指標均有改善，同治療前比較差異有統(tǒng)計學意義（P<0.05）；且觀察組心功能、運動耐力明顯優(yōu)于對照A組、對照B組；觀察組NT-pro BNP水平、心率及血壓均明顯低于對照A組、對照B組；觀察組Hb含量高于對照A組、對照組B組，差異均有統(tǒng)計學意義（P<0.05）。觀察組總有效率為95.72%，明顯高于對照A組的71.43%和對照B組的72.86%，差異均有統(tǒng)計學意義（P<0.05）。3組不良反應發(fā)生率相比，差異無統(tǒng)計學意義（P > 0.05）；結論 美托洛爾聯合貝那普利治療CHF可有效改善患者心功能，緩解心衰，提高患者運動耐力，具有臨床應用價值。

Objective To analyze the effect of betaloc combined with lotensin on cardiac function and N-terminal B type natriuretic peptide (NT-proBNP) level in patients with chronic congestive heart failure (CHF). Methods 210 CHF patients in People's Hospital in Qinghai Province from December 2015 to December 2016 were divided into three groups by random number table, 70 cases in each. Three group were given routine examination, cardiotonic and diuretic treatment, and on this basis, control A group purely added lotensin, control B group purely added betaloc, observation goup took betaloc combined with lotensin. The cardiac function, exercise tolerance, NT-proBNP level, concentration of hemoglobin (Hb), heart rate, blood pressure, clinical efficacy and safety before and after treatment were compared among the three groups. Results Before treatment, there was no statistical difference in the cardiac function, NT-pro BNP level and Hb content among three groups; After treatment, the cardiac function and exercise tolerance of observation group were significantly better than those of control A and B group (P < 0.05) The NT-pro BNP level, heart rate and blood pressure of observation group were significantly lower than those of control A and B group (P < 0.05) The Hb content of observation group was higher than that of control A and B group (P < 0.05). The total effective rate of observation group was significantly higher than that of control A and B group (P < 0.05). There was no statistical difference in the incidence of adverse reactions among three groups. Conclusion Betaloc combined with lotensin in treatment of CHF can effectively improve cardiac function, relieve heart failure and increase exercise tolerance of patients, which has clinical application value.